The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 17 and set a price target of ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

In a report released on March 14, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis AG (NOVN – Research Report), with a ...

Independent Advisor Alliance raised its holdings in Novartis AG (NYSE:NVS – Free Report) by 23.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC.

February 25, 2025 Sandoz family foundation offers $3 billion worth of Novartis shares Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against other best global stocks to buy according to hedge funds. The United States has long been a magnet for ...

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Novartis AG (NYSE:NVS – Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 54,767 call options on the stock. This represents an increase of 2,389% ...